Stonegate Investment Group LLC Has $3.53 Million Stock Holdings in Thermo Fisher Scientific Inc. (NYSE:TMO)

Stonegate Investment Group LLC grew its holdings in Thermo Fisher Scientific Inc. (NYSE:TMO) by 0.3% in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 6,788 shares of the medical research company’s stock after buying an additional 18 shares during the quarter. Stonegate Investment Group LLC’s holdings in Thermo Fisher Scientific were worth $3,531,000 as of its most recent filing with the SEC.

A number of other hedge funds also recently made changes to their positions in the business. Patrick M Sweeney & Associates Inc. increased its position in shares of Thermo Fisher Scientific by 2.1% during the 4th quarter. Patrick M Sweeney & Associates Inc. now owns 1,066 shares of the medical research company’s stock worth $555,000 after purchasing an additional 22 shares in the last quarter. Curbstone Financial Management Corp acquired a new stake in shares of Thermo Fisher Scientific during the 4th quarter worth about $685,000. Revolve Wealth Partners LLC increased its position in shares of Thermo Fisher Scientific by 4.2% during the 4th quarter. Revolve Wealth Partners LLC now owns 491 shares of the medical research company’s stock worth $255,000 after purchasing an additional 20 shares in the last quarter. YHB Investment Advisors Inc. increased its position in shares of Thermo Fisher Scientific by 0.4% during the 4th quarter. YHB Investment Advisors Inc. now owns 46,450 shares of the medical research company’s stock worth $24,165,000 after purchasing an additional 200 shares in the last quarter. Finally, Nilsine Partners LLC increased its position in shares of Thermo Fisher Scientific by 4.6% during the 4th quarter. Nilsine Partners LLC now owns 10,665 shares of the medical research company’s stock worth $5,548,000 after purchasing an additional 473 shares in the last quarter. Institutional investors and hedge funds own 89.23% of the company’s stock.

Thermo Fisher Scientific Stock Up 1.5 %

Shares of Thermo Fisher Scientific stock opened at $583.43 on Tuesday. Thermo Fisher Scientific Inc. has a 1 year low of $493.30 and a 1 year high of $627.88. The company has a debt-to-equity ratio of 0.64, a current ratio of 1.63 and a quick ratio of 1.26. The company has a market capitalization of $223.16 billion, a P/E ratio of 36.58, a price-to-earnings-growth ratio of 3.82 and a beta of 0.76. The business has a 50-day moving average of $533.60 and a two-hundred day moving average of $569.81.

Thermo Fisher Scientific declared that its Board of Directors has authorized a stock repurchase program on Friday, November 15th that allows the company to buyback $4.00 billion in shares. This buyback authorization allows the medical research company to purchase up to 2% of its shares through open market purchases. Shares buyback programs are often a sign that the company’s leadership believes its shares are undervalued.

Thermo Fisher Scientific Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Wednesday, January 15th. Shareholders of record on Friday, December 13th were paid a $0.39 dividend. This represents a $1.56 dividend on an annualized basis and a yield of 0.27%. The ex-dividend date was Friday, December 13th. Thermo Fisher Scientific’s payout ratio is currently 9.78%.

Insider Transactions at Thermo Fisher Scientific

In other news, CEO Marc N. Casper sold 5,850 shares of the company’s stock in a transaction dated Friday, November 1st. The stock was sold at an average price of $557.89, for a total transaction of $3,263,656.50. Following the completion of the transaction, the chief executive officer now directly owns 121,192 shares of the company’s stock, valued at $67,611,804.88. This represents a 4.60 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders sold 34,850 shares of company stock valued at $19,123,197 over the last quarter. Corporate insiders own 0.34% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities research analysts recently issued reports on TMO shares. Evercore ISI dropped their target price on shares of Thermo Fisher Scientific from $630.00 to $620.00 and set an “outperform” rating for the company in a research report on Thursday, October 24th. Royal Bank of Canada decreased their price objective on shares of Thermo Fisher Scientific from $767.00 to $718.00 and set an “outperform” rating on the stock in a report on Thursday, October 24th. Stephens assumed coverage on shares of Thermo Fisher Scientific in a report on Tuesday, October 1st. They set an “overweight” rating and a $680.00 price objective on the stock. Sanford C. Bernstein raised shares of Thermo Fisher Scientific from a “market perform” rating to an “outperform” rating and set a $630.00 price objective on the stock in a report on Friday, January 10th. Finally, Stifel Nicolaus decreased their price objective on shares of Thermo Fisher Scientific from $680.00 to $665.00 and set a “buy” rating on the stock in a report on Thursday, October 24th. Four equities research analysts have rated the stock with a hold rating, eighteen have issued a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $648.95.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.